Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:006071111 | Endometrium | EEC | labyrinthine layer development | 12/2168 | 44/18723 | 3.42e-03 | 2.32e-02 | 12 |
GO:000941015 | Endometrium | EEC | response to xenobiotic stimulus | 73/2168 | 462/18723 | 3.55e-03 | 2.38e-02 | 73 |
GO:004513711 | Endometrium | EEC | development of primary sexual characteristics | 40/2168 | 227/18723 | 4.43e-03 | 2.86e-02 | 40 |
GO:000840611 | Endometrium | EEC | gonad development | 39/2168 | 221/18723 | 4.78e-03 | 3.02e-02 | 39 |
GO:00075847 | Endometrium | EEC | response to nutrient | 32/2168 | 174/18723 | 5.35e-03 | 3.31e-02 | 32 |
GO:00219874 | Endometrium | EEC | cerebral cortex development | 23/2168 | 114/18723 | 5.41e-03 | 3.32e-02 | 23 |
GO:004484911 | Endometrium | EEC | estrous cycle | 6/2168 | 16/18723 | 6.84e-03 | 3.96e-02 | 6 |
GO:003087912 | Endometrium | EEC | mammary gland development | 26/2168 | 137/18723 | 7.50e-03 | 4.20e-02 | 26 |
GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
GO:000170119 | Esophagus | ESCC | in utero embryonic development | 243/8552 | 367/18723 | 1.00e-15 | 6.86e-14 | 243 |
GO:0071496111 | Esophagus | ESCC | cellular response to external stimulus | 215/8552 | 320/18723 | 4.29e-15 | 2.43e-13 | 215 |
GO:0031668111 | Esophagus | ESCC | cellular response to extracellular stimulus | 168/8552 | 246/18723 | 4.93e-13 | 2.23e-11 | 168 |
GO:001839413 | Esophagus | ESCC | peptidyl-lysine acetylation | 123/8552 | 169/18723 | 6.58e-13 | 2.94e-11 | 123 |
GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
GO:000647313 | Esophagus | ESCC | protein acetylation | 140/8552 | 201/18723 | 4.37e-12 | 1.69e-10 | 140 |
GO:0031669110 | Esophagus | ESCC | cellular response to nutrient levels | 148/8552 | 215/18723 | 4.58e-12 | 1.76e-10 | 148 |
GO:0048732111 | Esophagus | ESCC | gland development | 269/8552 | 436/18723 | 7.81e-12 | 2.95e-10 | 269 |
GO:0031667111 | Esophagus | ESCC | response to nutrient levels | 289/8552 | 474/18723 | 9.25e-12 | 3.47e-10 | 289 |
GO:001839313 | Esophagus | ESCC | internal peptidyl-lysine acetylation | 114/8552 | 158/18723 | 1.16e-11 | 4.24e-10 | 114 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0491520 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
hsa0491918 | Cervix | CC | Thyroid hormone signaling pathway | 33/1267 | 121/8465 | 3.11e-04 | 1.65e-03 | 9.78e-04 | 33 |
hsa05224 | Cervix | CC | Breast cancer | 32/1267 | 147/8465 | 1.66e-02 | 4.88e-02 | 2.88e-02 | 32 |
hsa04915110 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
hsa0491919 | Cervix | CC | Thyroid hormone signaling pathway | 33/1267 | 121/8465 | 3.11e-04 | 1.65e-03 | 9.78e-04 | 33 |
hsa052241 | Cervix | CC | Breast cancer | 32/1267 | 147/8465 | 1.66e-02 | 4.88e-02 | 2.88e-02 | 32 |
hsa04919 | Colorectum | AD | Thyroid hormone signaling pathway | 51/2092 | 121/8465 | 1.71e-05 | 1.73e-04 | 1.10e-04 | 51 |
hsa049191 | Colorectum | AD | Thyroid hormone signaling pathway | 51/2092 | 121/8465 | 1.71e-05 | 1.73e-04 | 1.10e-04 | 51 |
hsa049192 | Colorectum | SER | Thyroid hormone signaling pathway | 40/1580 | 121/8465 | 1.02e-04 | 1.06e-03 | 7.67e-04 | 40 |
hsa04915 | Colorectum | SER | Estrogen signaling pathway | 38/1580 | 138/8465 | 6.51e-03 | 3.68e-02 | 2.67e-02 | 38 |
hsa049193 | Colorectum | SER | Thyroid hormone signaling pathway | 40/1580 | 121/8465 | 1.02e-04 | 1.06e-03 | 7.67e-04 | 40 |
hsa049151 | Colorectum | SER | Estrogen signaling pathway | 38/1580 | 138/8465 | 6.51e-03 | 3.68e-02 | 2.67e-02 | 38 |
hsa049194 | Colorectum | MSS | Thyroid hormone signaling pathway | 46/1875 | 121/8465 | 5.04e-05 | 4.97e-04 | 3.05e-04 | 46 |
hsa049152 | Colorectum | MSS | Estrogen signaling pathway | 48/1875 | 138/8465 | 4.23e-04 | 3.08e-03 | 1.89e-03 | 48 |
hsa049195 | Colorectum | MSS | Thyroid hormone signaling pathway | 46/1875 | 121/8465 | 5.04e-05 | 4.97e-04 | 3.05e-04 | 46 |
hsa049153 | Colorectum | MSS | Estrogen signaling pathway | 48/1875 | 138/8465 | 4.23e-04 | 3.08e-03 | 1.89e-03 | 48 |
hsa049196 | Colorectum | MSI-H | Thyroid hormone signaling pathway | 21/797 | 121/8465 | 4.18e-03 | 4.10e-02 | 3.44e-02 | 21 |
hsa049197 | Colorectum | MSI-H | Thyroid hormone signaling pathway | 21/797 | 121/8465 | 4.18e-03 | 4.10e-02 | 3.44e-02 | 21 |
hsa049198 | Colorectum | FAP | Thyroid hormone signaling pathway | 41/1404 | 121/8465 | 2.28e-06 | 4.28e-05 | 2.60e-05 | 41 |
hsa049199 | Colorectum | FAP | Thyroid hormone signaling pathway | 41/1404 | 121/8465 | 2.28e-06 | 4.28e-05 | 2.60e-05 | 41 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NCOA1 | SNV | Missense_Mutation | | c.2923N>A | p.Pro975Thr | p.P975T | Q15788 | protein_coding | tolerated(0.06) | possibly_damaging(0.766) | TCGA-A2-A0YJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
NCOA1 | SNV | Missense_Mutation | novel | c.3535N>C | p.Thr1179Pro | p.T1179P | Q15788 | protein_coding | tolerated(0.2) | benign(0.269) | TCGA-A2-A1FW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
NCOA1 | SNV | Missense_Mutation | | c.258N>C | p.Glu86Asp | p.E86D | Q15788 | protein_coding | tolerated(0.43) | benign(0.105) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
NCOA1 | SNV | Missense_Mutation | novel | c.1729N>A | p.Pro577Thr | p.P577T | Q15788 | protein_coding | tolerated(0.08) | probably_damaging(0.941) | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NCOA1 | SNV | Missense_Mutation | | c.483N>A | p.His161Gln | p.H161Q | Q15788 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0XO-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
NCOA1 | SNV | Missense_Mutation | novel | c.1256A>C | p.Asn419Thr | p.N419T | Q15788 | protein_coding | tolerated(0.14) | benign(0.201) | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NCOA1 | SNV | Missense_Mutation | | c.4321G>A | p.Glu1441Lys | p.E1441K | Q15788 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.978) | TCGA-C8-A27B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
NCOA1 | SNV | Missense_Mutation | | c.3938N>G | p.Asn1313Ser | p.N1313S | Q15788 | protein_coding | tolerated(0.2) | possibly_damaging(0.86) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
NCOA1 | SNV | Missense_Mutation | novel | c.2646N>T | p.Gln882His | p.Q882H | Q15788 | protein_coding | deleterious(0.05) | possibly_damaging(0.601) | TCGA-OL-A5D8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NCOA1 | insertion | Nonsense_Mutation | novel | c.1730_1731insTTAAATTATTTGTATTAGGGAGACAAGGGAAG | p.Ala578Ter | p.A578* | Q15788 | protein_coding | | | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8648 | NCOA1 | ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR COMPLEX | | TCMDC-123764 | CHEMBL533226 | |
8648 | NCOA1 | ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR COMPLEX | | ETOPOSIDE | ETOPOSIDE | |
8648 | NCOA1 | ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR COMPLEX | inhibitor | 252827441 | | |
8648 | NCOA1 | ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR COMPLEX | | METHYLTHIONINIUM CHLORIDE | METHYLTHIONINIUM CHLORIDE | |
8648 | NCOA1 | ENZYME, CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, NUCLEAR HORMONE RECEPTOR, TRANSCRIPTION FACTOR COMPLEX | | tamoxifen | TAMOXIFEN | 22174377 |